Ophthalmic formulation
    33.
    发明授权
    Ophthalmic formulation 失效
    眼科配方

    公开(公告)号:US5597559A

    公开(公告)日:1997-01-28

    申请号:US329808

    申请日:1994-10-26

    IPC分类号: A61K9/00 A61K31/765 A61K9/08

    CPC分类号: A61K9/0048

    摘要: A preservative-free ophthalmic composition useful in the treatment of conditions such as dry eye comprising an aqueous solution of hydroxypropyl methylcellulose, polyethylene glycol, dextrose, potassium chloride, boric acid and sodium borate decahydrate.

    摘要翻译: 一种防腐剂的眼用组合物,其可用于治疗诸如干眼症的病症,包括羟丙基甲基纤维素,聚乙二醇,右旋糖,氯化钾,硼酸和硼酸钠十水合物的水溶液。

    Cyclosporin compositions
    34.
    发明授权

    公开(公告)号:US08563518B2

    公开(公告)日:2013-10-22

    申请号:US13536479

    申请日:2012-06-28

    摘要: A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols, ethoxylated alkylphenols, ethoxylated aryl phenols, ethoxylated fatty acids, ethoxylated fatty acids, ethoxylated fatty esters and oils, fatty alcohols, fatty esters, glycol esters, lanolin-based derivatives, lecithin and lecithin derivatives, lignin and lignin derivatives, methyl esters, monoglycerides and derivatives, phosphalipids, polyacrylic acids, polyethylene glycols, polyethylene oxide-polypropylene oxide copolymers, polyethylene oxides, polymeric surfactants, polypropylene oxides, propoxylated alcohols, propoxylated alkyl phenols, propoxylated fatty acids, protein-based surfactants, sarcosine derivatives, silicone-based surfactants, sorbitan derivatives, stearates, sucrose and glucose esters and derivatives, and combinations thereof.

    Cyclosporin compositions
    36.
    发明授权
    Cyclosporin compositions 有权
    环孢菌素组合物

    公开(公告)号:US08211855B2

    公开(公告)日:2012-07-03

    申请号:US11857223

    申请日:2007-09-18

    IPC分类号: A61K38/12

    摘要: A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols, ethoxylated alkylphenols, ethoxylated aryl phenols, ethoxylated fatty acids, ethoxylated fatty esters and oils, fatty alcohols, fatty esters, glycol esters, lanolin-based derivatives, lecithin and lecithin derivatives, lignin and lignin derivatives, methyl esters, monoglycerides and derivatives, phospholipids, polyacrylic acids, polyethylene glycols, polyethylene oxide-polypropylene oxide copolymers, polyethylene oxides, polymeric surfactants, polypropylene oxides, propoxylated alcohols, propoxylated alkyl phenols, propoxylated fatty acids, protein-based surfactants, sarcosine derivatives, silicone-based surfactants, sorbitan derivatives, stearates, sucrose and glucose esters and derivatives, and combinations thereof.

    摘要翻译: 本文公开了一种组合物,其包含约0.001%至约0.4%的环孢菌素A,蓖麻油和选自醇乙氧基化物,醇,烷基糖苷,烷基多糖苷,烷基酚乙氧基化物,氧化胺,嵌段聚合物,羧化的 醇或烷基酚乙氧基化物,羧酸/脂肪酸,纤维素衍生物,乙氧基化醇,乙氧基化烷基酚,乙氧基化芳基酚,乙氧基化脂肪酸,乙氧基化脂肪酯和油,脂肪醇,脂肪酯,乙二醇酯,羊毛脂基衍生物,卵磷脂和 卵磷脂衍生物,木质素和木质素衍生物,甲酯,单酸甘油酯和衍生物,磷脂,聚丙烯酸,聚乙二醇,聚环氧乙烷 - 聚环氧丙烷共聚物,聚环氧乙烷,聚合物表面活性剂,聚丙烯氧化物,丙氧基化醇,丙氧基化烷基酚,丙氧基化脂肪酸, 基于蛋白质的表面活性剂,肌氨酸衍生物 有机硅基表面活性剂,脱水山梨糖醇衍生物,硬脂酸盐,蔗糖和葡萄糖酯及其衍生物及其组合。

    COMPOSITIONS AND METHODS FOR LOCALIZED THERAPY OF THE EYE
    37.
    发明申请
    COMPOSITIONS AND METHODS FOR LOCALIZED THERAPY OF THE EYE 审中-公开
    眼睛局部治疗的组合物和方法

    公开(公告)号:US20120142652A1

    公开(公告)日:2012-06-07

    申请号:US13367070

    申请日:2012-02-06

    IPC分类号: A61K31/58 A61P27/02 B82Y5/00

    摘要: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.

    摘要翻译: 提供了组合物和使用这种组合物的方法,其可用于注射到人或动物眼睛的后段中。 这样的组合物包括促进在眼睛的视网膜色素上皮中形成治疗剂的浓缩区域的难溶性治疗剂的小颗粒。 通过将治疗剂与眼科可接受的聚合物组分组合来形成颗粒。 颗粒具有小于约3000纳米的尺寸,并且在一些情况下小于约200纳米。 组合物的一个实例包括曲安奈德的颗粒和透明质酸的尺寸小于约3000纳米。